74 related articles for article (PubMed ID: 27101755)
1. The time of resolution and the rate of recurrence in acute central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy: a case-control study.
Ozkaya A; Alkin Z; Ozveren M; Yazici AT; Taskapili M
Eye (Lond); 2016 Jul; 30(7):1005-10. PubMed ID: 27101755
[TBL] [Abstract][Full Text] [Related]
2. Half-dose photodynamic therapy versus 577 nm subthreshold pulse laser therapy in treatment-naive patients with central serous chorioretinopathy.
Sitnilska V; Schiller P; Krohne TU; Altay L
BMC Ophthalmol; 2024 Jan; 24(1):8. PubMed ID: 38178104
[TBL] [Abstract][Full Text] [Related]
3. Aniseikonia after reduced-fluence photodynamic therapy in patients with central serous chorioretinopathy.
Chubachi-Kamimura A; Miki A; Hayashida-Hirano M; Kishimoto-Kishi M; Okuda M; Matsumiya W; Imai H; Kusuhara S; Nakamura M
Sci Rep; 2023 Oct; 13(1):17133. PubMed ID: 37816824
[TBL] [Abstract][Full Text] [Related]
4. Optical coherence tomography angiography-guided vs indocyanine green angiography-guided half-dose photodynamic therapy for acute central serous chorioretinopathy: 6-month randomized trial results.
Li S; Zhang L; Tang J; Wang Z; Qu J; Zhao M
Graefes Arch Clin Exp Ophthalmol; 2023 Nov; 261(11):3149-3158. PubMed ID: 37347247
[TBL] [Abstract][Full Text] [Related]
5. Comparison of prevalent management options to treat acute central serous chorioretinopathy.
Pradhan AK; Behera UC
Indian J Ophthalmol; 2023 Nov; 71(11):3563-3568. PubMed ID: 37870025
[TBL] [Abstract][Full Text] [Related]
6. Spontaneous Resolution of Chronic Central Serous Chorioretinopathy: "Fuji Sign".
Feenstra HMA; Hensman J; Gkika T; Lipkova V; Hoyng CB; Diederen RMH; Schlingemann RO; Downes SM; van Dijk EHC; Boon CJF
Ophthalmol Retina; 2022 Sep; 6(9):861-863. PubMed ID: 35533974
[No Abstract] [Full Text] [Related]
7. The Uses of Photodynamic Therapy Versus Anti-vascular Endothelial Growth Factor in the Management of Acute Central Serous Chorioretinopathy: A Systematic Review and Meta-Analysis.
Seraj H; Alhamoud M; Khoshhal MS; Alhashim H; Alsaif A; Abukhashabah A
Cureus; 2023 Sep; 15(9):e46100. PubMed ID: 37900481
[TBL] [Abstract][Full Text] [Related]
8. An Update on the Diagnosis and Management of Central Serous Chorioretinopathy.
Liu DT; Fok AT; Lam DS
Asia Pac J Ophthalmol (Phila); 2012; 1(5):296-302. PubMed ID: 26107601
[TBL] [Abstract][Full Text] [Related]
9. Current Therapeutic Approaches to Chronic Central Serous Chorioretinopathy.
Gülkaş S; Şahin Ö
Turk J Ophthalmol; 2019 Feb; 49(1):30-39. PubMed ID: 30829023
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Efficacy and Safety of Photodynamic Therapy in Patients With Chronic Central Serous Chorioretinopathy.
Park YJ; Kim YK; Park KH; Woo SJ
Ophthalmic Surg Lasers Imaging Retina; 2019 Dec; 50(12):760-770. PubMed ID: 31877221
[TBL] [Abstract][Full Text] [Related]
11. Central Serous Chorioretinopathy: Pathogenesis and Management.
Semeraro F; Morescalchi F; Russo A; Gambicorti E; Pilotto A; Parmeggiani F; Bartollino S; Costagliola C
Clin Ophthalmol; 2019; 13():2341-2352. PubMed ID: 31819359
[TBL] [Abstract][Full Text] [Related]
12. An international collaborative evaluation of central serous chorioretinopathy: different therapeutic approaches and review of literature. The European Vitreoretinal Society central serous chorioretinopathy study.
Romano MR; Parolini B; Allegrini D; Michalewska Z; Adelman R; Bonovas S; Bopp S;
Acta Ophthalmol; 2020 Aug; 98(5):e549-e558. PubMed ID: 31808315
[TBL] [Abstract][Full Text] [Related]
13. Central serous chorioretinopathy: Towards an evidence-based treatment guideline.
van Rijssen TJ; van Dijk EHC; Yzer S; Ohno-Matsui K; Keunen JEE; Schlingemann RO; Sivaprasad S; Querques G; Downes SM; Fauser S; Hoyng CB; Piccolino FC; Chhablani JK; Lai TYY; Lotery AJ; Larsen M; Holz FG; Freund KB; Yannuzzi LA; Boon CJF
Prog Retin Eye Res; 2019 Nov; 73():100770. PubMed ID: 31319157
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapy of Central Serous Chorioretinopathy: A Review of the Current Treatments.
Iacono P; Toto L; Costanzo E; Varano M; Parravano MC
Curr Pharm Des; 2018; 24(41):4864-4873. PubMed ID: 30674250
[TBL] [Abstract][Full Text] [Related]
15. Screening strategies for atrial fibrillation: a systematic review and cost-effectiveness analysis.
Welton NJ; McAleenan A; Thom HH; Davies P; Hollingworth W; Higgins JP; Okoli G; Sterne JA; Feder G; Eaton D; Hingorani A; Fawsitt C; Lobban T; Bryden P; Richards A; Sofat R
Health Technol Assess; 2017 May; 21(29):1-236. PubMed ID: 28629510
[TBL] [Abstract][Full Text] [Related]
16. Subthreshold laser compared to oral spironolactone for the treatment of chronic central serous chorioretinopathy: a retrospective study.
Mercuri S; D'Alterio FM; Gallo B; Raslan W; Gupta A; Khairat N; Corazza P; Younis S
Int Ophthalmol; 2024 Mar; 44(1):131. PubMed ID: 38478131
[TBL] [Abstract][Full Text] [Related]
17. Widefield choroidal vasculature associated with future condition of subretinal fluid in central serous chorioretinopathy.
Kogo T; Muraoka Y; Ishikura M; Nishigori N; Ueda-Arakawa N; Miyata M; Tamura H; Hata M; Takahashi A; Miyake M; Tsujikawa A
Heliyon; 2023 Aug; 9(8):e18441. PubMed ID: 37576325
[TBL] [Abstract][Full Text] [Related]
18. Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies.
Zhang X; Lim CZF; Chhablani J; Wong YM
Eye Vis (Lond); 2023 Jul; 10(1):33. PubMed ID: 37430344
[TBL] [Abstract][Full Text] [Related]
19. Central serous chorioretinopathy: Treatment.
Park JB; Kim K; Kang MS; Kim ES; Yu SY
Taiwan J Ophthalmol; 2022; 12(4):394-408. PubMed ID: 36660123
[TBL] [Abstract][Full Text] [Related]
20. Interobserver Agreement of Novel Classification of Central Serous Chorioretinopathy.
Sahoo NK; Parameshwarappa DC; Jhingan M; Tatti F; Iovino C; Peiretti E
Cureus; 2022 Jun; 14(6):e25925. PubMed ID: 35844339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
